PDF herunterladen
J Neurol Surg B Skull Base 2018; 79(03): 262-268
DOI: 10.1055/s-0037-1607298
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Changing Trends in the Management of Esthesioneuroblastoma: Irish and International Perspectives

Robbie S. R. Woods
1   Department of ENT Surgery, Beaumont Hospital, Dublin 9, Ireland
,
Thavakumar Subramaniam
1   Department of ENT Surgery, Beaumont Hospital, Dublin 9, Ireland
,
Mary Leader
2   Department of Histopathology, Beaumont Hospital, Dublin 9, Ireland
,
Rory McConn-Walsh
1   Department of ENT Surgery, Beaumont Hospital, Dublin 9, Ireland
,
James Paul O'Neill
1   Department of ENT Surgery, Beaumont Hospital, Dublin 9, Ireland
,
Peter D. Lacy
1   Department of ENT Surgery, Beaumont Hospital, Dublin 9, Ireland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

13. Mai 2017

05. September 2017

Publikationsdatum:
01. November 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Objectives Evaluation of the changing trends in esthesioneuroblastoma in an Irish context and review of management options nationally to clarify the best current therapeutic approach by comparing with international research on this uncommon malignancy.

Design Retrospective review.

Setting Tertiary referral center.

Participants All patients presenting with esthesioneuroblastoma in Beaumont hospital or on the National Cancer Registry of Ireland between 1994 and 2013.

Main Outcome Measures Recurrence-free and overall survival.

Results During the study period, 32 cases of esthesioneuroblastoma were diagnosed (0.4 per million per year). Average age at diagnosis was 57 years; however, two cases were under 20. The majority (62.5%) were male. Patients predominantly presented with epistaxis or nasal congestion (73%), while two cases were identified incidentally on radiological investigations. Twenty-seven cases underwent primary surgical management (two post neo-adjuvant treatment) with seventeen requiring bifrontal craniotomy. Twenty-four of these received postoperative radiation therapy. Overall, 5-year survival was 65%. Kadish A/B patients exhibited 100% 5-year disease-specific survival versus 54% in Kadish C/D (p = 0.011). Hyams grade I/II patients exhibited 75% 5-year disease-specific survival versus 63% in Hyams grade III/IV (p = 0.005). Patients treated endoscopically exhibited 100% 5-year disease-specific survival versus 51% in those treated via an open approach (p = 0.102).

Conclusions Many controversies exist in the diagnosis and management of this condition. Despite this, results from Irish data are mostly concordant with the international literature. The rising incidence of this disease may represent improved pathological recognition. An increasing number of esthesioneuroblastoma cases are being successfully treated via endoscopic surgery.

Keywords

esthesioneuroblastoma - sinonasal malignancy - olfactory neuroblastoma - skull base

Note

This paper was presented at the American Head and Neck Society, 9th International Conference in Seattle, July 2016.


 

  • References

  • 1 Berger L, Luc H, Richard R. L'esthesioneuro epitheliome olfactif. Bull Assoc Fr Etud Cancer 1924; 13: 410-420
    PubMedGoogle Scholar
  • 2 Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003; 123 (03) 433-439
    CrossrefPubMedGoogle Scholar
  • 3 Petruzzelli GJ, Howell JB, Pederson A. , et al. Multidisciplinary treatment of olfactory neuroblastoma: patterns of failure and management of recurrence. Am J Otolaryngol 2015; 36 (04) 547-553
    CrossrefPubMedGoogle Scholar
  • 4 Shirzadi AS, Drazin DG, Strickland AS, Bannykh SI, Johnson JP. Vertebral column metastases from an esthesioneuroblastoma: chemotherapy, radiation, and resection for recurrence with 15-year followup. Case Rep Surg 2013; 2013: 107315
    PubMedGoogle Scholar
  • 5 Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997; 17 (4A): 2683-2706
    PubMedGoogle Scholar
  • 6 Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 2007; 133 (03) 276-280
    CrossrefPubMedGoogle Scholar
  • 7 Su SY, Bell D, Hanna EY. Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol 2014; 18 (Suppl. 02) S149-S156
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Tajudeen BA, Arshi A, Suh JD, St John M, Wang MB. Importance of tumor grade in esthesioneuroblastoma survival: a population-based analysis. JAMA Otolaryngol Head Neck Surg 2014; 140 (12) 1124-1129
    CrossrefPubMedGoogle Scholar
  • 9 Thompson LD. Olfactory neuroblastoma. Head Neck Pathol 2009; 3 (03) 252-259
    CrossrefPubMedGoogle Scholar
  • 10 Carney ME, O'Reilly RC, Sholevar B. , et al. Expression of the human Achaete-scute 1 gene in olfactory neuroblastoma (esthesioneuroblastoma). J Neurooncol 1995; 26 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 11 Ow TJ, Bell D, Kupferman ME, Demonte F, Hanna EY. Esthesioneuroblastoma. Neurosurg Clin N Am 2013; 24 (01) 51-65
    CrossrefPubMedGoogle Scholar
  • 12 Hwang SK, Paek SH, Kim DG, Jeon YK, Chi JG, Jung HW. Olfactory neuroblastomas: survival rate and prognostic factor. J Neurooncol 2002; 59 (03) 217-226
    CrossrefPubMedGoogle Scholar
  • 13 Song CM, Won TB, Lee CH, Kim DY, Rhee CS. Treatment modalities and outcomes of olfactory neuroblastoma. Laryngoscope 2012; 122 (11) 2389-2395
    CrossrefPubMedGoogle Scholar
  • 14 Nabili V, Kelly DF, Fatemi N, St John M, Calcaterra TC, Abemayor E. Transnasal, transfacial, anterior skull base resection of olfactory neuroblastoma. Am J Otolaryngol 2011; 32 (04) 279-285
    CrossrefPubMedGoogle Scholar
  • 15 Snyderman CH, Carrau RL, Kassam AB. , et al. Endoscopic skull base surgery: principles of endonasal oncological surgery. J Surg Oncol 2008; 97 (08) 658-664
    CrossrefPubMedGoogle Scholar
  • 16 Stammberger H, Anderhuber W, Walch C, Papaefthymiou G. Possibilities and limitations of endoscopic management of nasal and paranasal sinus malignancies. Acta Otorhinolaryngol Belg 1999; 53 (03) 199-205
    PubMedGoogle Scholar
  • 17 Folbe A, Herzallah I, Duvvuri U. , et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy 2009; 23 (01) 91-94
    CrossrefPubMedGoogle Scholar
  • 18 Tajudeen BA, Arshi A, Suh JD. , et al. Esthesioneuroblastoma: an update on the UCLA experience, 2002-2013. J Neurol Surg B Skull Base 2015; 76 (01) 43-49
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 19 Zanation AM, Ferlito A, Rinaldo A. , et al. When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. Eur Arch Otorhinolaryngol 2010; 267 (11) 1667-1671
    CrossrefPubMedGoogle Scholar
  • 20 Rosenthal DI, Barker Jr JL, El-Naggar AK. , et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 2004; 101 (11) 2567-2573
    CrossrefPubMedGoogle Scholar
  • 21 Hyams V, Batsakis J, Michaels L. Olfactory neuroblastoma. Tumors of the Upper Respiratory Tract and Ear, Atlas of Tumor Pathology. vol 25. Washington DC: Armed Forces Institute Press; 1988: 240-248
    Google Scholar
  • 22 Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001; 2 (11) 683-690
    CrossrefPubMedGoogle Scholar
  • 23 Saade RE, Hanna EY, Bell D. Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system. Curr Oncol Rep 2015; 17 (01) 423
    CrossrefPubMedGoogle Scholar
  • 24 Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37 (03) 1571-1576
    CrossrefPubMedGoogle Scholar
  • 25 Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 32 (05) 706-714 , discussion 714–715
    CrossrefPubMedGoogle Scholar
  • 26 Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope 1992; 102 (08) 843-849
    CrossrefPubMedGoogle Scholar
  • 27 Biller HF, Lawson W, Sachdev VP, Som P. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope 1990; 100 (11) 1199-1201
    PubMedGoogle Scholar
  • 28 Zafereo ME, Fakhri S, Prayson R. , et al. Esthesioneuroblastoma: 25-year experience at a single institution. Head Neck Surg 2008; 138 (04) 452-458
    CrossrefPubMedGoogle Scholar
  • 29 Bachar G, Goldstein DP, Shah M. , et al. Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head Neck 2008; 30 (12) 1607-1614
    CrossrefPubMedGoogle Scholar
  • 30 Senchak A, Freeman J, Ruhl D, Senchak J, Klem C. Low-grade esthesioneuroblastoma presenting as SIADH: a review of atypical manifestations. Case Rep Otolaryngol 2012; 2012: 582180
    PubMedGoogle Scholar
  • 31 Salmasi V, Schiavi A, Binder ZA. , et al. Intraoperative hypertensive crisis due to a catecholamine-secreting esthesioneuroblastoma. Head Neck 2015; 37 (06) E74-E80
    CrossrefPubMedGoogle Scholar
  • 32 Fu TS, Monteiro E, Muhanna N, Goldstein DP, de Almeida JR. Comparison of outcomes for open versus endoscopic approaches for olfactory neuroblastoma: a systematic review and individual participant data meta-analysis. Head Neck 2016; 38 (Suppl. 01) E2306-E2316
    CrossrefPubMedGoogle Scholar
  • 33 Shah JP, Patel SG, Singh B. Skull base. In: Shah JP. , ed. Jatin Shah's Head and Neck Surgery and Oncology. Philadelphia, PA: Elsevier; 2007: 171
    Google Scholar
  • 34 Benfari G, Fusconi M, Ciofalo A. , et al. Radiotherapy alone for local tumour control in esthesioneuroblastoma. Acta Otorhinolaryngol Ital 2008; 28 (06) 292-297
    PubMedGoogle Scholar
  • 35 Foote RL, Morita A, Ebersold MJ. , et al. Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27 (04) 835-842
    CrossrefPubMedGoogle Scholar
  • 36 De Bonnecaze G, Lepage B, Rimmer J. , et al. Long-term carcinologic results of advanced esthesioneuroblastoma: a systematic review. Eur Arch Otorhinolaryngol 2016; 273 (01) 21-26
    CrossrefPubMedGoogle Scholar
  • 37 Bradley PJ, Jones NS, Robertson I. Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg 2003; 11 (02) 112-118
    CrossrefPubMedGoogle Scholar
  • 38 Polin RS, Sheehan JP, Chenelle AG. , et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery 1998; 42 (05) 1029-1037
    CrossrefPubMedGoogle Scholar
  • 39 Sohrabi S, Drabick JJ, Crist H, Goldenberg D, Sheehan JM, Mackley HB. Neoadjuvant concurrent chemoradiation for advanced esthesioneuroblastoma: a case series and review of the literature. J Clin Oncol 2011; 29 (13) e358-e361
    CrossrefPubMedGoogle Scholar
  • 40 Ferlito A, Rinaldo A, Rhys-Evans PH. Contemporary clinical commentary: esthesioneuroblastoma: an update on management of the neck. Laryngoscope 2003; 113 (11) 1935-1938
    PubMedGoogle Scholar
  • 41 Demiroz C, Gutfeld O, Aboziada M, Brown D, Marentette LJ, Eisbruch A. Esthesioneuroblastoma: is there a need for elective neck treatment?. Int J Radiat Oncol Biol Phys 2011; 81 (04) e255-e261
    CrossrefPubMedGoogle Scholar
  • 42 Banuchi VE, Dooley L, Lee NY. , et al. Patterns of regional and distant metastasis in esthesioneuroblastoma. Laryngoscope 2016; 126 (07) 1556-1561
    CrossrefPubMedGoogle Scholar
  • 43 Naples JG, Spiro J, Tessema B, Kuwada C, Kuo CL, Brown SM. Neck recurrence and mortality in esthesioneuroblastoma: implications for management of the N0 neck. Laryngoscope 2016; 126 (06) 1373-1379
    CrossrefPubMedGoogle Scholar
  • 44 Gore MR, Zanation AM. Salvage treatment of late neck metastasis in esthesioneuroblastoma: a meta-analysis. Arch Otolaryngol Head Neck Surg 2009; 135 (10) 1030-1034
    CrossrefPubMedGoogle Scholar
  • 45 Ohtakara K, Hoshi H. Long-term tumor control despite late pseudoprogression on(18)F-FDG-PET following extremely hypofractionated stereotactic radiotherapy for retropharyngeal lymph node metastasis from esthesioneuroblastoma. Case Rep Oncol 2014; 7 (02) 576-582
    CrossrefPubMedGoogle Scholar
  • 46 Simon JH, Zhen W, McCulloch TM. , et al. Esthesioneuroblastoma: the University of Iowa experience 1978-1998. Laryngoscope 2001; 111 (03) 488-493
    CrossrefPubMedGoogle Scholar
  • 47 Jiang W, Mohamed AS, Fuller CD. , et al. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol 2016; 6 (04) 241-247
    CrossrefPubMedGoogle Scholar
  • 48 Diensthuber M, Potinius M, Rodt T. , et al. Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma. J Neurooncol 2008; 89 (02) 131-139
    CrossrefPubMedGoogle Scholar
  • 49 Fukushima S, Sugita Y, Niino D, Mihashi H, Ohshima K. Clincopathological analysis of olfactory neuroblastoma. Brain Tumor Pathol 2012; 29 (04) 207-215
    CrossrefPubMedGoogle Scholar
  • 50 Bak M, Wein RO. Esthesioneuroblastoma: a contemporary review of diagnosis and management. Hematol Oncol Clin North Am 2012; 26 (06) 1185-1207
    CrossrefPubMedGoogle Scholar